Catalyst Dossier · compiled by CeliA 🧫

PTC Therapeutics, Inc. (PTCT)

Pharmaceutical Preparations · market cap $655M

Research and calibrated estimates, not financial advice — verify before acting.

Next catalyst

2026-08-06

Earnings

Pipeline

programs

Upcoming events

next 90d+

Dossier

Not yet

generate it

The catalyst path

2026-08-06Earningsimp 5/10

Pipeline

Asset	Phase	Indication
Ataluren	Phase 3	Duchenne Muscular Dystrophy
EPI-743	Phase 2	Leigh Syndrome
PTC923	Phase 3	BH4 Deficiency
EPI-589	Phase 2	Amyotrophic Lateral Sclerosis
EPI-743 400 mg	Phase 2	Friedreich's Ataxia
EPI-743 15 mg/kg	Phase 2	Leigh Syndrome
CNSA-001	Phase 2	Gastroparesis
Ataluren (PTC124®)	Phase 3	Cystic Fibrosis
Vatiquinone	Phase 3	Friedreich Ataxia
Sepiapterin	Phase 3	Phenylketonuria
PTC124	Phase 2	Cystic Fibrosis

Price & technical context

3-month

+21.2%

6-month

+9.3%

12-month

+69.8%

52-wk range

$43.30–$86.25

vs 50-day MA

+14.1%

vs 200-day MA

+16.5%

Realized vol

59.9%

Max drawdown

-36.7%

Daily closes through 2026-07-02. Realized vol annualized; max drawdown over ~2 years.

The full dossier is a Pro feature

Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.

See Pro

Sources & data

SEC filings — EDGAR filings for PTCT (10-K, 10-Q, S-3, 13D/G, Form 4)
Clinical trials — 11 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
Market & financial data — Financial Modeling Prep / financialdata.net — prices, statements, key metrics, insider & institutional filings.
Regulatory — openFDA, FDA advisory & PDUFA calendars.

Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.

Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, Financial Modeling Prep). Compiled by CeliA. Not financial advice.